Review article · 2025 · Open access
Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review
Journal of Rheumatic Diseases, 33(4), 238–254 · Published 26 December 2025 · DOI 10.4078/jrd.2025.0075
In brief
“Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review” is a 2025 review article by Faryal Razzaq and 8 co-authors, published in Journal of Rheumatic Diseases. OpenAlex counts 0 citations as of 19 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Journal of Rheumatic Diseases.
- Citations
- 0
- References
- 38
- Authors
- 9
Abstract
Autoimmune diseases such as systemic lupus erythematosus (SLE), arise when the immune system inappropriately attacks the body's own tissues, leading to chronic inflammation and significant morbidity. Traditional treatments, including corticosteroids, immunosuppressive drugs, and biologic agents, often provide incomplete disease control and are associated with substantial side effects. Chimeric Antigen Receptor (CAR) T-cell therapy, which targets and eliminates autoreactive B cells, has emerged as a promising novel approach for these conditions. This review evaluates the efficacy, safety, and therapeutic potential of CAR T-cell therapy in SLE and other autoimmune diseases, focusing on recent the most recent clinical studies. The review shows significant clinical improvements and sustained remissions in patients with severe, refractory autoimmune conditions, particularly with CD19 and B Cell Maturation Antigen (BCMA)-targeted CAR T-cell preparations. The review also examines adverse effects and safety profiles, emphasizing the differences in toxicity between cancer patients and those with autoimmune diseases. Overall, the findings highlight the transformative potential of CAR T-cell therapy in autoimmune diseases management, offering new possibilities for more effective and longer-lasting disease control while underscoring the need for further research to optimize therapy protocols and better understand long-term outcomes and safety.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Razzaq, F., Ahmad, R. U., Iftikhar, A., Gondal, F. R., Rehman, M. E. U., Suhaib, M., Ali, M. K., Vina, E. R., & Husnain, M. (2025). Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review. Journal of Rheumatic Diseases, 33(4), 238–254. https://doi.org/10.4078/jrd.2025.0075
MLA 9
Razzaq, Faryal, et al. “Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review.” Journal of Rheumatic Diseases, vol. 33, no. 4, 2025, pp. 238–254. https://doi.org/10.4078/jrd.2025.0075.
Chicago
Razzaq, Faryal, Rana Uzair Ahmad, Ahmad Iftikhar, Farva Razia Gondal, Mohammad Ebad Ur Rehman, Muhammad Suhaib, M. Khawar Ali, Ernest R. Vina, and Muhammad Husnain. 2025. “Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review.” Journal of Rheumatic Diseases 33 (4): 238–254. https://doi.org/10.4078/jrd.2025.0075.
Harvard
Razzaq, F. et al. (2025) ‘Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review’, Journal of Rheumatic Diseases, 33(4), pp. 238–254. doi:10.4078/jrd.2025.0075.
IEEE
F. Razzaq et al., “Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review,” Journal of Rheumatic Diseases, vol. 33, no. 4, pp. 238–254, 2025, doi: 10.4078/jrd.2025.0075.
BibTeX
@article{razzaq2025chimeric,
title = {{Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review}},
author = {Razzaq, Faryal and Ahmad, Rana Uzair and Iftikhar, Ahmad and Gondal, Farva Razia and Rehman, Mohammad Ebad Ur and Suhaib, Muhammad and Ali, M. Khawar and Vina, Ernest R. and Husnain, Muhammad},
journal = {Journal of Rheumatic Diseases},
year = {2025},
volume = {33},
number = {4},
pages = {238--254},
doi = {10.4078/jrd.2025.0075},
url = {https://doi.org/10.4078/jrd.2025.0075}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- CAR T-cell therapy
- systemic lupus erythematosus
- autoimmune disease
- CD19 CAR T cells
- autoreactive B cells
- refractory autoimmune disease
- remission
- CAR T-cell toxicity
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Razzaq, F., Ahmad, R. U., Iftikhar, A., Gondal, F. R., Rehman, M. E. U., Suhaib, M., Ali, M. K., Vina, E. R., & Husnain, M. (2025). Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review. Journal of Rheumatic Diseases, 33(4), 238–254. https://doi.org/10.4078/jrd.2025.0075
How many times has this paper been cited?
0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Rheumatic Diseases: sign in and open the PDF from this page.
Who wrote this paper?
Faryal Razzaq, Rana Uzair Ahmad, Ahmad Iftikhar, Farva Razia Gondal, Mohammad Ebad Ur Rehman, Muhammad Suhaib, M. Khawar Ali, Ernest R. Vina, Muhammad Husnain.
What is the DOI of this paper?
10.4078/jrd.2025.0075, permanently at https://doi.org/10.4078/jrd.2025.0075. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.